Study Evaluating Refacto For Pharmacovigilance

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Factor VIII

Criteria

Inclusion Criteria:

• Proven diagnosis of Hemophilia A

Exclusion Criteria:

• Contraindications according to Summary of Product Characteristics